Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia.

•In total, 909 patients with heterozygous familial hypercholesterolemia received alirocumab (median duration 2.5 years).•Alirocumab dose received (75 or 150 milligrams) based on clinical judgment of physician.•Seventy-five milligram dose considered enough for low-density lipoprotein cholesterol control for 56.7% of patients by physicians.•During open-label extension, 5.9% of patients reported local injection-site reaction adverse events.•Physician's decision to increase alirocumab dose was primarily due to high low-density lipoprotein cholesterol.